Brief: A1M Pharma successfully conducts preclinical toxicology/safety studies within preeclampsia

Disruptive Pharma AB (publ)

29/11/2016 14:54

Nov 29 (Reuters) - A1M Pharma AB  A1M.ST : 
    * Says has successfully and according to plan conducted the first part of the company's 
toxicology/safety studies with the pharmaceutical compound in the company's candidate drug 
ROSGard 
    * In the studies, a maximum tolerated dose (MTD) has been established in two different 
animal models  
    * These results will be used to establish the dosage levels to be used in the GLP-compliant 
toxicology studies 
 
     
 Source text: http://bit.ly/2gFcqeQ 
     
 Further company coverage:  A1M.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))